A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy

Study acronym: STAY SEC PsO
StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Novartis
556 trials monitored
See 32 trials at risk
Psoriasis
593 trials monitored
See 24 trials at risk
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in patients receiving secukinumab monotherapy. The study will also evaluate adherence, long-term treatment retention, and healthcare resource utilization.
Trial Details
NCT Number NCT07881783
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Plaque Psoriasis
Related terms Treatment Adherence and Compliance
Enrollment 3,718 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov